Please assess the completion status of the following clinical trial:

Trial Title: Perampanel in Focal Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 18 years or above, including the protected adults with a focal motor status epilepticus, defined by prominent clinically objective focal motor symptoms (clonic, tonic, myoclonic, adversive or oculoclonic), lasting for more than 10 minutes before any treatment or repeated focal motor seizures during this period (≥ 4 seizures in 10 min)~2. The focal motor status continues (or patients show ≥ 2 focal motor seizures) 5 minutes or more after the beginning of administration of benzodiazepines. The delay between administration of benzodiazepines and randomization must not exceed 6 hours.~3. Affiliation to a French social security system (recipient or assign) excluding Aide Médicale Etat (AME)~Exclusion Criteria:~1. Known severe liver (Factor V \<50 %) or kidney (glomerular filtration rate : 15-29 ml/min/1,72 m2) insufficiency~2. Women with known or clinically detected pregnancy~3. Patients with known allergies to perampanel or to any of the excipients mentioned in the summary of product characteristics(SmPC)~4. Patients with postanoxic status~5. Patients in coma (Glasgow\<8)~6. Patients with motor events for which a nonepileptic psychogenic origin is suspected~7. Patients whose status epilepticus is linked to a pathological condition, such as trauma, who needed immediate surgery~8. Known current treatment by perampanel~9. Known galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases)~10. Known participation in another trial with medication and/or previously included in PEPSI study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): immediate enteral administration of Perampanel, 12 mg
- Placebo (Type: PLACEBO_COMPARATOR): immediate enteral administration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).